1. A contact field for a plug-in connection for twisted-pair cabling equipped with several metallic contacts (4) for a connection with a twisted-pair socket, with each metallic contact (4) having a feed line section (6) for a connection with a circuit board (2), characterized in that:
the metallic contacts (4) are formed from contact plates and that at least two of the feed line sections (6; 23, 26) are arranged offset relative to other feed line sections (6; 21, 22, 24, 25, 27, 28).
2. A contact field according to claim 1, characterized in that the contact field is equipped with eight metallic contacts (4).
3. A contact field according to claim 1 or 2, characterized in that the third and sixth feed line section of the feed line sections (23, 26) are arranged offset relative to adjacent feed line sections (22, 24, 25, 27).
4. A contact field according to claim 1, characterized in that the contacts (4) and the respective feed line sections (6) are executed in one piece.
5. Contact field according to claim 1, characterized in that the contact field is an RJ45 contact field.
6. Contact field according to claim 1, characterized in that the contact field is suitable to meet the specifications under CAT6a.
7. Contact field according to claim 1, characterized in that the contact field is moreover equipped with a housing made of insulating material.
8. Contact field according to claim 1, characterized in that the contact field is part of a print panel plug.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
We claim:
1. A process for delivering a polynucleotide to a parenchymal cell in a mammalian limb in vivo, comprising:
a) inserting the polynucleotide into a blood vessel of the limb;
b) applying pressure to the limb epidermis to impede fluid flow in the vessel; and,
c) delivering the polynucleotide into the parenchymal cell.
2. The process of claim 1 wherein inserting the polynucleotide results in increasing the permeability of blood vessels in the limb.
3. The process of claim 2 wherein increasing the permeability consists of increasing a volume of fluid within the limb.
4. The process of claim 3 wherein increasing the volume consists of inserting a solution containing the polynucleotide into the blood vessel.
5. The process of claim 4 wherein increased permeability is controlled by altering the rate of insertion of the volume into the vessel.
6. The process of claim 1 wherein applying pressure to the limb epidermis consists of applying an external cuff.
7. The process of claim 1 wherein the cell is selected from the group consisting of a an arm skeletal muscle cell and a leg skeletal muscle cell.
8. A process for delivering a polynucleotide complexed with a compound into a parenchymal cell of a mammal in vivo, comprising:
a) making a polynucleotide-compound complex wherein the zeta potential of the complex is less negative than the polynucleotide alone;
b) adding another compound to the complex to increase zeta potential negativity of the complex from the previous step;
c) inserting the complex into a blood vessel of the limb;
d) applying pressure to the limb epidermis to impede fluid flow in the vessel; and,
e) delivering the polynucleotide into the parenchymal cell; and,
f) expressing the polynucleotide.
9. The process of claim 8 wherein inserting the complex results in increasing the permeability of the blood vessels in the limb.
10. The process of claim 9 wherein increasing the permeability consists of increasing a volume of fluid within the limb.
11. The process of claim 10 wherein increasing the volume consists of inserting a solution containing the polynucleotide into the blood vessel.
12. The process of claim 11 wherein a specific volume of the solution is inserted within a specific time period.
13. The process of claim 12 wherein increased permeability is controlled by altering the volume of the solution in relation to the time period of insertion.
14. The process of claim 8 wherein applying pressure to the limb epidermis consists of applying an external cuff.
15. The process of claim 8 wherein the cell is selected from the group consisting of an arm skeletal muscle cell and a leg skeletal muscle cell.
16. The process of claims 1 or 8 wherein the polynucleotide is inserted in at least a 1 milliliter solution.
17. The process of claims 1 or 8 wherein the the process additionally comprises administering immunosuppressive treatment to the mammal.
18. The process of claim 6 or 14 wherein the cuff is selected from the group consisting of a tourniquet and a sphygmomanometer.